The new US health aid comes with strings — and some African governments are saying no

Biotech & Longevity 4 min 7 sources

Washington is offering African nations billions to build their own health systems, but the money is tied to conditions on data, drugs, and minerals — and several countries are refusing while the WHO-run fight against Ebola in Congo carries on.

Key takeaways

The US is offering African nations billions to build their own health systems, but the money is tied to conditions on drug purchases, health data, and even mineral access — and Ghana, Zimbabwe, and Zambia have refused to sign.
The core fight is over control: countries worry that handing over patient data and disease samples means losing say over what's done with them, a lesson many drew from struggling to get Covid vaccines.
While governments negotiate the terms, the diseases don't wait — a WHO-run Ebola treatment trial has begun in Congo amid more than 1,400 cases, and Uganda has just confirmed a Marburg death.

A gift, or a deal?

The United States is again offering hundreds of millions of dollars to African countries to build up their health systems and fight disease. This week the US signed a memorandum with Tanzania to invest more than $1.3 billion over five years [2]. It follows similar pacts with Kenya, Rwanda, and Uganda under the Trump administration’s “America First Global Health Strategy,” which aims to make poorer nations self-reliant instead of dependent on aid [2].

The difference from the old model is the conditions. Under the new strategy, a recipient government has to raise its own health spending to match — Tanzania committed $1.8 billion of its own over the same period [2]. Kenya’s deal is worth $2.5 billion, with the US putting in $1.6 billion and Kenya pledging $850 million [1]. The stated goal is durable systems that can eventually run themselves [1].

But the deals also carry terms that go well beyond health. The policy document calls the aid “a strategic mechanism to further our bilateral interests,” and the agreements come with an explicit promise to prioritise US drug and medical firms [1]. In Zambia, the government says Washington tried to bundle the health deal with a separate agreement giving the US access to critical minerals; Zambia refused to sign [1].

Why several governments are refusing

Thirty-two countries had accepted the health agreements by mid-May, at least 20 of them in Africa [1]. But Ghana, Zimbabwe, and Zambia have held back [1].

The sharpest objection is over data. The deals ask countries to share patients’ medical information and biological samples — pathogens, meaning the viruses, bacteria, and parasites that cause disease [1]. Ghana’s data-protection chief said his country was being asked to hand over data with “no real reciprocal measures” to protect Ghanaian sovereignty: “once the data left the Ghanaian borders, we had no control over what becomes of it” [1]. Zimbabwe cited the same worry, noting there was no guarantee that drugs or vaccines developed from its pathogens would be available to its own people [1]. A Kenyan court initially suspended that country’s deal over patient-privacy challenges before ministers approved it [1].

The US says the material requested is the same de-identified data used for years against infectious disease [1]. What has changed, one global-health researcher told the BBC, is the context: an unequal relationship that once read as altruism now reads as “very transactional leverage” [1]. More than 50 civil society groups signed an open letter warning that the US terms were not guided by African interests [1].

The same logic, running the other way

The idea that health data and clinical trials are strategic assets is not only a US-to-Africa story. This week a bipartisan group of US lawmakers opened national-security investigations into five drugmakers, including Merck and AbbVie, over clinical trials run in China [5]. The China Select Committee asked the companies to detail data-protection and due-diligence standards at trial sites, particularly in Xinjiang and at military hospitals [5]. Whatever the merits, it is the same premise seen from Washington’s side of the table: where medical data flows, and who controls it, is now treated as a matter of national power [5].

Meanwhile, the disease doesn’t wait

While governments negotiate the terms of cooperation, the outbreaks continue on the old, WHO-run track. A trial of two potential treatments for the strain of Ebola behind the current outbreak in the Democratic Republic of Congo began this week, sponsored by the World Health Organization [3]. There are more than 1,400 confirmed cases and 438 deaths in the DRC, plus 20 cases and two deaths in Uganda [3]. There is no approved vaccine or treatment for this particular strain, the Bundibugyo virus [3]. The trial is co-ordinated by researchers in Congo, Belgium, and the UK [3][7].

The region is stretched. Uganda, already fighting the Ebola outbreak, this week confirmed an isolated case of Marburg — a related, highly infectious hemorrhagic fever — in a toddler who died [4]. Responding to Marburg takes the same steps as Ebola, and the same people [4].

Both of these responses run through the WHO, the body the US withdrew from early this year [1]. Many African nations drew a hard lesson from Covid: the race for a vaccine proved how valuable their pathogen data was, yet left the continent struggling to get doses [1]. That memory is shaping how they read the fine print now.

One quiet piece of progress

Away from the geopolitics, a reminder of what the underlying science is for. Researchers at Johns Hopkins reported an experimental nose-spray DNA vaccine for tuberculosis, designed to help the immune system attack the drug-tolerant “persister” bacteria that survive long antibiotic courses and cause relapse [6]. In animal studies it cleared infections faster and prevented relapse [6]. It is early — animal-stage work, not yet in people — and most things that work in animals never reach patients [6]. But TB still kills more people than almost any other infection, and the tools to fight it are exactly the kind of durable capacity every one of these deals claims to be about.

02 · Lesson · why it matters

The most important term in any deal is who keeps control

Money that arrives with conditions isn't only a gift — it's a claim on the future, and the real question is who gets to decide what happens next.

A strange thing to refuse

Here is something that looks, at first, like a mistake. A poor country is offered more than a billion dollars to build hospitals, fight disease, and train its own health workers. And it says no.

Zambia turned it down. Ghana and Zimbabwe held back. Not because they don’t need the money — they badly do. They refused because of what the money was attached to. The offer came bundled with terms: buy from American drug firms, hand over your patients’ medical data, share your disease samples, in one case even open up your minerals. The dollars were real. But so were the strings.

To understand why a government would walk away from that, you have to stop seeing the money as the thing being exchanged. The money is the easy part. The thing actually changing hands is control.

A gift and a deal are not the same shape

We use the word “aid” for both, and that hides the difference.

A gift is closed. It happens once, it’s over, and afterwards you owe nothing. A deal is open. It reaches into the future and sets terms on what you can do next — who you buy from, what you share, who decides. A billion dollars given freely and a billion dollars lent against your data are the same number on paper and completely different things in the world.

The old model was closer to a gift, or at least it was sold that way. An outside agency funded a clinic and ran it. It was unequal — the country never had much say — but the inequality was quiet. You could tell your own people it was help. What changed this year isn’t the amount. It’s that the terms came out into the open. The new deals say plainly that the aid is “strategic capital to advance US interests.” Once that’s said out loud, everyone can see the shape underneath, and the shape is a claim.

The asset you didn’t know you were holding

The hardest condition to accept was about data. Not money, not drugs — information. Who gets to keep the record of a country’s diseases, and the physical samples of the viruses and bacteria themselves.

This sounds abstract until you remember what happened in the last pandemic. When Covid arrived, the world raced to build vaccines, and that race ran on exactly this kind of data — genetic sequences, patient records, samples from the earliest cases. Africa supplied a great deal of it. Then, when the vaccines existed, the continent stood at the back of the queue for doses.

That is the lesson those governments are working from now. Your disease data is not a byproduct. It is a raw material — as real as a mineral in the ground. Hand it over without terms, and you may find that the medicine built from it is sold back to you, if it reaches you at all. A country that once thought of its outbreaks as pure misfortune is now learning to see them as something it owns. Refusing the deal is what owning something looks like.

The same rule, seen from the other chair

It would be easy to read this as a story about a powerful country pressuring weaker ones. It’s bigger than that. The same logic is running in the opposite direction at the same moment.

This week American lawmakers opened an investigation into US drug companies for running clinical trials in China — worried about who controlled the medical data generated there, near military hospitals. The exact fear Ghana voiced about handing data to Washington, Washington now voices about its own firms handing data to Beijing.

That symmetry is the tell. This isn’t one greedy party and one wronged one. It’s a whole system quietly reclassifying health information as a strategic asset — something too valuable to let cross a border without knowing who ends up in charge of it. Everyone is starting to guard the same thing, because everyone has worked out it’s worth guarding.

What has to survive between the deals

Step back and there’s a cost that lands on no one in the negotiating room. While governments spend months arguing over terms, the diseases don’t pause to wait for a signature.

Right now there is an Ebola outbreak in Congo — more than 1,400 cases, no approved treatment for this strain — and a treatment trial has only just begun. Next door, Uganda just lost a small child to Marburg, a cousin of Ebola, while it was already stretched fighting the first outbreak. That trial is being run the old way, through the World Health Organization, by researchers in three countries pooling what they know. It works only because those groups still trust that shared effort will be there when a virus arrives, and that no single country holds the whole thing hostage.

And that is the quiet thing at stake underneath all the money. A health system isn’t only buildings and drugs. It’s a standing promise — that the clinic will open next year, that a sample sent to a lab will come back as a treatment, that the people you cooperate with won’t disappear when the politics shift. The countries refusing these deals aren’t rejecting help. They’re protecting the one thing a pile of conditional dollars can’t buy: the confidence that the arrangement will still hold when they need it most.

We are all somewhere inside this. The next outbreak won’t check anyone’s passport, and no single seat at the table — not Washington’s, not Zambia’s, not the lab’s — can see the whole board. Which is why the terms of a deal you’ll never sign still matter to you. When trust between the players thins, the thing that frays is the very net meant to catch us all.

03 · Lab · your turn

The Terms of the Deal

Rehearse a health minister weighing conditional aid — feel the trade between the money you need and the control you can't get back.

04 · Hope · carry this

Notice what the refusals are really made of: countries that have learned their own worth, and now bargain for their people instead of simply hoping for scraps. And even as the terms are argued over, three nations' scientists are sitting together in Congo, running an Ebola trial the old way — proof that when a virus threatens everyone, people still find the will to pool what they know.